AB Corporate Bond ETF (NASDAQ:EYEG) Share Price Crosses Below Two Hundred Day Moving Average – Here’s What Happened

AB Corporate Bond ETF (NASDAQ:EYEG)’s share price crossed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $35.33 and traded as low as $34.56. AB Corporate Bond ETF shares last traded at $34.56, with a volume of 1,723 shares trading hands.

AB Corporate Bond ETF Trading Up 0.1%

The company has a current ratio of 3.07, a quick ratio of 3.07 and a debt-to-equity ratio of 0.01. The firm has a 50-day moving average price of $35.01 and a 200-day moving average price of $35.32. The company has a market capitalization of $27.70 million, a price-to-earnings ratio of -20.61 and a beta of 0.18.

AB Corporate Bond ETF Increases Dividend

The company also recently announced a monthly dividend, which was paid on Thursday, August 6th. Investors of record on Monday, August 3rd were issued a dividend of $0.1427 per share. The ex-dividend date of this dividend was Monday, August 3rd. This is an increase from AB Corporate Bond ETF’s previous monthly dividend of $0.14. This represents a c) dividend on an annualized basis and a yield of 4.9%. AB Corporate Bond ETF’s dividend payout ratio is presently -102.38%.

Institutional Investors Weigh In On AB Corporate Bond ETF

An institutional investor recently raised its stake in AB Corporate Bond ETF stock. Jane Street Group LLC grew its holdings in shares of AB Corporate Bond ETF (NASDAQ:EYEG) by 166.7% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 15,741 shares of the specialty pharmaceutical company’s stock after purchasing an additional 9,839 shares during the period. Jane Street Group LLC owned approximately 2.10% of AB Corporate Bond ETF worth $563,000 as of its most recent filing with the Securities and Exchange Commission. 64.16% of the stock is owned by institutional investors and hedge funds.

About AB Corporate Bond ETF

EyeGate Pharmaceuticals, Inc is a clinical stage specialty pharmaceutical company, which engages in the development and commercialization of products for treating diseases and disorders of the eye. Its pipeline includes MoxiGel and Ocular Bandage Gel. The company was founded in 1998 and is headquartered in Waltham, MA.